Dow Pharma and Food Solutions (DPFS) and Sirius Analytical Announce Strategic Agreement
Dow Pharma and Food Solutions (DPFS) and Sirius Analytical Announce Strategic Agreement to Offer Biorelevant Equivalence Testing on FloVitro™ Platform
London, UK and Midland, MI, 14 November 2016 – Dow Pharma and Food Solutions, a business unit within The Dow Chemical Company (NYSE: DOW), and Sirius Analytical Instruments Ltd, a leading provider of tools and professional services to support drug discovery, development and formulation today announced a strategic agreement to allow Sirius Analytical to offer services performed on Dow’s FloVitroTM Biorelevant dissolution platform.
The FloVitro™ technology was born after Dow’s pharmaceutical customers searched for a better way to establish in-vitro in-vivo correlation for their formulations. FloVitro™ is Dow’s unique technology that uses in vitro biorelevant dissolution test methods to establish level A in vitro in vivo correlation (IVIVC) of immediate release formulations, enabling applications such as predicting the effect of formulation changes (like extended release) and determining the effect of gastro-intestinal changes on dissolution. This technology also allows for innovator equivalence studies for generic drug formulations, giving testers a more representative idea of what happens in the body. The agreement will help bring this innovative technology to new customers, by combining the knowledge and expertise of Dow with the equipment and testing know-how and customer base of Sirius.
“We are thrilled to now be able to offer the sophisticated FloVitro™ technology to our customers, and to work with such a prestigious partner as Dow. Since the FDA, MHRA and other regulatory bodies began encouraging companies to investigate more biorelevant formulation strategies, Sirius have worked closely with key opinion leaders globally to research and develop innovative tools to assist our clients to do such work,” said Paul Whittles, Managing Director of Sirius Analytical. “Dow’s scientists share our collaborative and open approach that we always strive to foster, making them a true partner.”
“We began developing the FloVitro™ system in 1999 when the very idea of biorelevant dissolution experimentation was in its infancy. Our agreement with Sirius will enable more customers around the globe to utilize this unique, innovative technology,” said Christophe Massip, Global Marketing Director for Dow Pharma & Food Solutions. “When searching for a partner to elevate and expand the reach this technology, Sirius was the obvious choice. Sirius shares our same principles and integrity, and is one of the best connected companies in the biorelevant formulation/testing space. We feel confident entrusting this offering to them.”
The agreement is effective immediately, with testing available at Sirius Analytical location in the U.K. For additional information, visit Sirius at www.sirius-analytical.com or Dow’s website at dowpharmasolutions.com or visit Sirius or Dow at AAPS in Denver, Colorado, USA on 13-17 November 2016.
About Sirius Analytical
Sirius Analytical is a market leader in the fields of measurement of physicochemical properties, biorelevant solubility and dissolution and in vitro modelling of in vivo behaviour of formulated biological drugs. Our expertise areas include the delivery of oral, inhaled, injected and transdermal drugs.
Sirius also offers analytical and consultancy services to help our customers solve all kinds of small and large molecule formulation challenges.
About Dow Pharma & Food Solutions (DPFS)
Dow Pharma & Food Solutions (DPFS) designs differentiated solutions that enable pharmaceutical delivery & nutritional benefits to customers around the world. A business of Dow Consumer Care portfolio, Dow Pharma & Food Solutions offers a single interface to all Dow technologies and expertise focused on solutions serving the pharmaceutical and food manufacturing markets. We provide functional excipients, active pharmaceutical ingredients (APIs) and highly functional food ingredients to help consumers live healthier, more convenient and enjoyable lives. Dow Pharma & Food Solutions employs 1,200 people across nine sites and 15 manufacturing plants, with six cGMPs, serving customers in around 160 countries.
Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company is driving innovations that extract value from material, polymer, chemical and biological science to help address many of the world's most challenging problems such as the need for clean water, clean energy generation and conservation, and increasing agricultural productivity. Dow's integrated, market-driven, industry-leading portfolio of specialty chemical, advanced materials, agrosciences and plastics businesses delivers a broad range of technology-based products and solutions to customers in approximately 180 countries and in high-growth sectors such as packaging, electronics, water, coatings and agriculture. In 2015, Dow had annual sales of nearly $49 billion and employed approximately 49,500 people worldwide. The Company's more than 6,000 product families are manufactured at 179 sites in 35 countries across the globe. On June 1, 2016, Dow became the 100 percent owner of Dow Corning Corporation’s silicones business, a global company with sales of greater than $4.5 billion in 2015, 25 manufacturing sites in 9 countries and approximately 10,000 employees worldwide. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com.
For more information:
® ™Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow